Zacks Investment Research upgraded shares of Innovus Pharmaceuticals, Inc. (OTCMKTS:INNV) from a hold rating to a buy rating in a research report sent to investors on Thursday morning.

According to Zacks, “Innovus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. It delivers non-prescription medicine and consumer care products to improve men’s and women’s health and vitality. It has a robust portfolio of sexual dysfunction treatments, cough, cold, respiratory disease treatments and pain management medication, as well as skin care products. Its male and female sexual health and vitality products include Zestra (R) to increase desire, arousal, and satisfaction in women; EjectDelay (R) for treating premature ejaculation; Sensum+ (TM) that increases penile sensitivity; Zestra Glide (R); and Vesele (R) to maximize nitric oxide beneficial effects on sexual functions and brain health. Innovus Pharmaceuticals, Inc. is based in San Diego, California. “

Shares of Innovus Pharmaceuticals (INNV) opened at $0.09 on Thursday. Innovus Pharmaceuticals has a 12 month low of $0.08 and a 12 month high of $0.39.

Innovus Pharmaceuticals (OTCMKTS:INNV) last released its earnings results on Tuesday, November 14th. The company reported ($0.01) earnings per share for the quarter. Innovus Pharmaceuticals had a negative return on equity of 330.39% and a negative net margin of 102.95%. The business had revenue of $2.22 million for the quarter. equities analysts anticipate that Innovus Pharmaceuticals will post -0.04 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Innovus Pharmaceuticals, Inc. (INNV) Lifted to “Buy” at Zacks Investment Research” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/innovus-pharmaceuticals-inc-innv-lifted-to-buy-at-zacks-investment-research/1726630.html.

Innovus Pharmaceuticals Company Profile

Innovus Pharmaceuticals, Inc is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners.

Get a free copy of the Zacks research report on Innovus Pharmaceuticals (INNV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Innovus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innovus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.